Mesothelioma Science News
San Pedro, CA - October 18, 2007
1. Intensity-modulated radiation therapy and
3D-conformal radiation therapy are both suitable for
mesothelioma.
Link here.
2. Alpha-TOS ineffective at inhibiting tumour development
mice with peritoneal mesothelioma, and results in severe
side effects.
Link here.
3. Patient with rare pericardial mesothelioma extends
average 6-month survival to 16 months with carboplaint +
pemetrexed regimen.
Link here.
4. Tumor serum markers CEA and SMRP were able to
discriminate with high sensitivity between mesothelioma and
non-small cell lung cancer; Cyfra 21.1 proved useful
discriminating between normal versus malignancy.
Link here.
5. Risk of mesothelioma increases from second-hand asbestos
expoure, but mortality from lung cancer does not increase.
Link here.
|